BTIG keeps USD 178 target for Nektar Therapeutics stock

Published on 10/20/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nektar guided to USD 815 million to USD 840 million cash at year-end. Nektar Therapeutics stock costs EUR 34.33 on October 20, 2026.

Analyst target and cash outlook

BTIG maintained a USD 178.00 target for Nektar Therapeutics on October 9, 2026.
Nektar expects USD 815 million to USD 840 million in cash and investments at year-end 2026.
Nektar Therapeutics stock stood at EUR 34.33 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST.

NKTR, US6402683063, Illustration mit AI erstellt.

Nektar Therapeutics (US6402683063) has a USD 178.00 price target from BTIG, which maintained its Buy rating in a report dated October 9, 2026, according to The Globe and Mail. The company also expects cash and investments of USD 815 million to USD 840 million at year-end 2026. Nektar stock was trading at EUR 34.33 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST.

BTIG keeps its USD 178 target

The BTIG view adds a fresh analyst reference to Nektar's clinical-stage biotechnology story. The October 9 report kept the Buy rating and the USD 178.00 target, while Nektar's shares had closed at USD 41.17 on the previous Friday, according to The Globe and Mail. The target is one of several recent analyst views on the company, but this report is the latest BTIG statement cited in the published coverage.

Cash supports the clinical pipeline

Nektar's second-quarter 2026 revenue was USD 10.10 million, while its net loss was USD 40.60 million, according to the company's second-quarter earnings call transcript dated August 13, 2026, published by Yahoo Finance. Management said the second-quarter cash and investments balance was USD 1.02 billion and projected USD 815 million to USD 840 million at year-end.

The same call identified early 2027 as the planned start for the phase three alopecia areata study and mid-2028 for initial data from the phase three atopic dermatitis program, according to Yahoo Finance. Those milestones give the cash forecast a direct connection to the company's development schedule.

Nasdaq range frames the valuation

On the Nasdaq, Nektar last traded at USD 38.70 on October 20, 2026 at 3:50 p.m. EDT. Its market capitalization was USD 1.1 billion, daily volume was 610,072 shares, and the 52-week range was USD 33.40 to USD 109.00 on that date. The current quote sits above the yearly low and below the yearly high, leaving clinical execution as the central valuation variable.

What comes next for Nektar

Nektar is advancing rezpegaldesleukin in autoimmune and inflammatory diseases, with atopic dermatitis and alopecia areata as the lead programs. The second-quarter call said the company had no debt and expected its cash runway to extend into the third quarter of 2028, providing a dated financing reference alongside the analyst target.

Stock price and trading context

Nektar Therapeutics was trading at EUR 34.33 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST. The euro quotation provides the latest German-market view, while the Nasdaq quote stood at USD 38.70 at 3:50 p.m. EDT on the same date.

The further course of trading is shown by the continuously updated real-time quote of Nektar Therapeutics stock.